Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. [electronic resource]

By: Contributor(s): Publication details: Infectious diseases and therapy Dec 2018Description: 473-484 p. digitalISSN:
  • 2193-8229
Online resources: In: Infectious diseases and therapy vol. 7
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.